Abstract
Coxsackievirus strain CVB3 is widespread in the human population and causes myocarditis or pancreatitis. However, despite its clinical impact, there is no commercially available and clinically applicable prophylactic vaccine. This study examines the characteristics of attenuated CVB3 strains developed so far and their application as live-attenuated CVB3 vaccines, and discusses problems to be overcome in the development of live-attenuated vaccines.
| Original language | English |
|---|---|
| Pages (from-to) | 179-190 |
| Number of pages | 12 |
| Journal | Expert Opinion on Biological Therapy |
| Volume | 10 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2010 |
Bibliographical note
Funding Information:This work was supported by grants from the Korea Centers for Disease Control and Prevention, the Gyeonggi Regional Research Center (GRRC) of the Catholic University of Korea, Korea Rural Development Administration and the Ministry of Knowledge Economy (MKE) and Korea Industrial Technology Foundation (KOTEF) through the Human Resource Training Project for Strategic Technology.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Attenuation
- Coxsackievirus B3
- Vaccine
Fingerprint
Dive into the research topics of 'Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live-attenuated vaccines'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver